Urinary levels of regenerating islet-derived protein III Β and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats

Kidney International

Volumn 79, Issue 5, 2011, Pages 518-528

  Ferreira, Laura ^a   Quiros, Yaremi ^b,c   Sancho Martínez, Sandra M ^b,c   García Sánchez, Omar ^b,c   Raposo, Cesar ^b   López Novoa, Jose M ^b,c   González Buitrago, Jose M ^a   López Hernández, Francisco J ^a,b,c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Instituto Reina Sofía de Investigación Nefrológica   (Spain)

Author keywords

acute kidney injury; gelsolin; gentamicin; reg IIIb; urinary markers

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CREATININE; GELSOLIN; GENTAMICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOGENIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGERATING ISLET DERIVED PROTEIN 3 BETA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; PROTEOMICS; RAT;

EID: 79951672135     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.439     Document Type: Article

References (69)

1. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007; 223: 86-98. (Pubitemid 47211265)
2. Kacew S, Bergeron MG. Pathogenic factors in aminoglycoside-induced nephrotoxicity. Toxicol Lett 1990; 51: 241-259. (Pubitemid 20141914)
3. Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990; 40: 2383-2392.
4. Leehey DJ, Braun BI, Tholl DA et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol 1993; 4: 81-90.
5. Nakakuki M, Yamasaki F, Shinkawa T et al. Protective effect of human ulinastatin against gentamicin-induced acute renal failure in rats. Can J Physiol Pharmacol 1996; 74: 104-111.
6. Rodriguez-Barbero A, Lopez-Novoa JM, Arevalo M. Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Exp Nephrol 1997; 5: 47-54. (Pubitemid 27105123)
7. Luft FC, Evan AP. Glomerular filtration barrier in aminoglycoside-induced nephrotoxic acute renal failure. Ren Physiol 1980; 3: 265-271. (Pubitemid 11132129)
8. Schor N, Ichikawa I, Rennke HG et al. Pathophysiology of altered glomerularfunction in aminoglycoside-treated rats. Kidney Int 1981; 19: 288-296. (Pubitemid 11145610)
9. Smaoui H, Mallie JP, Cheignon M et al. Glomerular alterations in rat neonates after transplacental exposure to gentamicin. Nephron 1991; 59: 626-631.
10. Kohn S, Fradis M, Ben-David J et al. Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol 2002; 26: 371-382. (Pubitemid 36016045)
11. Kent AL, Maxwell LE, Koina ME et al. Renal glomeruli and tubular injury following indomethacin, ibuprofen, and gentamicin exposure in a neonatal rat model. Pediatr Res 2007; 62: 307-312. (Pubitemid 47301480)
12. Klotman PE, Yarger WE. Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin. Kidney Int 1983; 24: 638-643. (Pubitemid 14208760)
13. Goto T, Fujigaki Y, Sun DF etal. Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats. Virchows Arch 2004; 444: 362-374. (Pubitemid 38553642)
14. Secilmis MA, Karatas Y, Yorulmaz O et al. Protective effect of L-arginine intake on the impaired renal vascular responses in the gentamicin-treated rats. Nephron Physiol 2005; 100: p13-p20. (Pubitemid 40868664)
15. Hishida A, Nakajima T, Yamada M et al. Roles of hemodynamic and tubular factors in gentamicin-mediated nephropathy. Ren Fail 1994; 16: 109-116. (Pubitemid 24341117)
16. Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 2005; 17: 193-199. (Pubitemid 40516099)
17. Baylis C The mechanism of the decline in glomerular filtration rate in gentamicin-induced acute renal failure in the rat. J Antimicrob Chemother 1980; 6: 381-388. (Pubitemid 10076866)
18. Avasthi PS, Evan AP, Huser JW et al. Effect of gentamicin on glomerular ultrastructure. J Lab Clin Med 1981; 98: 444-454. (Pubitemid 11049477)
19. Coimbra TM, Lachat JJ. Analysis of urinary albumin excretion in gentamicin-treated rats. Nephron 1988; 49: 154-159.
20. De-Barros-e-Silva ML, Varanda WA, Lachat JJ et al. Glomerular permeability to macromolecules in gentamicin-treated rats. Braz J Med Biol Res 1992; 25: 409-417.
21. Cheung CM, Ponnusamy A, Anderton JG. Management of acute renal failure in the elderly patient: a clinician's guide. Drugs Aging 2008; 25: 455-476. (Pubitemid 351812256)
22. Papanikolaou N, Peros G, Morphake P et al. Does gentamicin induce acute renal failure by increasing renal TXA2 synthesis in rats? Prostaglandins Leukot Essent Fatty Acids 1992; 45: 131-136.
23. Lopez-Novoa JM. Potential role of platelet activating factor in acute renal failure. Kidney Int 1999; 55: 1672-1682. (Pubitemid 29197954)
24. Nakajima T, Hishida A, Kato A. Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats. Am J Physiol 1994; 266: F425-F431.
25. Valdivielso JM, Rivas-Cabanero L, Morales AI et al. Increased renal glomerular endothelin-1 release in gentamicin-induced nephrotoxicity. Int J Exp Pathol 1999; 80: 265-270.
26. Terlouw SA, Masereeuw R, Russel FG et al. Nephrotoxicants induce endothelin release and signaling in renal proximal tubules: effect on drug efflux. Mol Pharmacol 2001; 59: 1433-1440. (Pubitemid 32510108)
27. Kellum JA, Levin N, Bouman C et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002; 8: 509-514. (Pubitemid 35388204)
28. Bellomo R, Kellum JA, Ronco C Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 2007; 33: 409-413. (Pubitemid 46333828)
29. Binswanger U. Acute renal failure: changing causes? Kidney Blood Press Res 1997; 20: 163. (Pubitemid 27390000)
30. Block CA, Schoolwerth AC The epidemiology and outcome of acute renal failure and the impact on chronic kidney disease. Semin Dial 2006; 19: 450-454. (Pubitemid 44736550)
31. Kellum JA, Hoste EA. Acute kidney injury: epidemiology and assessment. Scand J Clin Lab Invest Suppl 2008; 241: 6-11. (Pubitemid 351883670)
32. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008; 3: 844-861.
33. Neild GH. Multi-organ renal failure in the elderly. Int Urol Nephrol 2001; 32: 559-565. (Pubitemid 34272316)
34. Adabag AS, Ishani A, Koneswaran S et al. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. Am Heart J 2008; 155: 1143-1149.
35. Duru M, Nacar A, Yonden Z et al. Protective effects of N-acetylcysteine on cyclosporine-A-induced nephrotoxicity. Ren Fail 2008; 30: 453-459. (Pubitemid 351868690)
36. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008; 3: 281-287.
37. Luo J, Tsuji T, Yasuda H et al. The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats. Nephrol Dial Transplant 2008; 23: 2198-2205. (Pubitemid 351957613)
38. Hartmann JT, Kollmannsberger C, Kanz L et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866-869.
39. Keyes R, Bagshaw SM. Early diagnosis of acute kidney injury in critically ill patients. Expert Rev Mol Diagn 2008; 8: 455-464. (Pubitemid 351962090)
40. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48: 463-493. (Pubitemid 351738161)
41. Waikar SS, Bonventre JV. Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract 2008; 109: c192-c197.
42. Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology 2008; 245: 182-193.
43. Cataldi L, Mussap M, Verlato G et al. Netilmicin effect on urinary retinol binding protein (RBP) and N-acetyl-beta-D-glucosaminidase (NAG) in preterm newborns with and without anoxia. J Chemother 2002; 14: 76-83. (Pubitemid 34262702)
44. Dennen P, Parikh CR. Biomarkers of acute kidney injury: can we replace serum creatinine? Clin Nephrol 2007; 68: 269-278. (Pubitemid 350047759)
45. Silverblatt FJ, Kuehn C Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979; 15: 335-345. (Pubitemid 10219854)
46. Beauchamp D, Gourde P, Bergeron MG. Subcellular distribution of gentamicin in proximal tubular cells, determined by immunogold labeling. Antimicrob Agents Chemother 1991; 35: 2173-2179.
47. Giurgea-Marion L, Toubeau G, Laurent G et al. Impairment of lysosome-pinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses. Toxicol Appl Pharmacol 1986; 86: 271-285. (Pubitemid 17190060)
48. Jones AT, Wessling-Resnick M. Inhibition of in vitro endosomal vesicle fusion activity by aminoglycoside antibiotics. J Biol Chem 1998; 273: 25301-25309. (Pubitemid 28443296)
49. Dieterle F, Marrer E, Suzuki E et al. Monitoring kidney safety in drug development: emerging technologies and their implications. Curr Opin Drug Discov Devel 2008; 11: 60-71.
50. Goodsaid FM. Identification and measurement of genomic biomarkers of nephrotoxicity. J Pharmacol Toxicol Methods 2004; 49: 183-186. (Pubitemid 38686656)
51. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin 2006; 22: 357-374. (Pubitemid 44308117)
52. Brivet FG, Kleinknecht DJ, Loirat P et al. Acute renal failure in intensive care units-causes, outcome, and prognosticfactors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24: 192-198. (Pubitemid 26065324)
53. Bonventre JV. Diagnosis of acute kidney injury: from classic parameters to new biomarkers. Contrib Nephrol 2007; 156: 213-219.
54. Bagshaw SM, Uchino S, Bellomo R, et al., Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care 2009; 24: 129-140.
55. Zhang YW, Ding LS, Lai MD. Reg gene family and human diseases. World J Gastroenterol 2003; 9: 2635-2641.
56. Stephanova E, Tissir F, Dusetti N et al. The rat genes encoding the pancreatitis-associated proteins I, II and III (Pap1, Pap2, Pap3), and the lithostathin/pancreatic stone protein/regeneration protein (Reg) colocalize at 4q33→q34. Cytogenet Cell Genet 1996; 72: 83-85.
57. Nata K, Liu Y, Xu L et al. Molecular cloning, expression and chromosomal localization of a novel human REG family gene, III REG. Gene 2004; 340: 161-170. (Pubitemid 39360242)
58. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999; 11: 103-108.
59. Spinardi L, Witke W. Gelsolin and diseases. Subcell Biochem 2007; 45: 55-69.
60. Silacci P, Mazzolai L, Gauci C et al. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004; 61: 2614-2623. (Pubitemid 39586521)
61. Bucki R, Levental I, Kulakowska A et al. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008; 9: 541-551.
62. Sakurai N, Utsumi T Posttranslational N-myristoylation is required for the anti-apoptotic activity of human tGelsolin, the C-terminal caspase cleavage product of human gelsolin. J Biol Chem 2006;281: 14288-14295. (Pubitemid 43848357)
63. Kothakota S, Azuma T, Reinhard C et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278: 294-298. (Pubitemid 27450877)
64. Boccellino M, Giuberti G, Quagliuolo L et al. Apoptosis induced by interferon-alpha and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J Cell Physiol 2004; 201: 71-83. (Pubitemid 39187046)
65. Cojocel C, Dociu N, Maita K et al. Effects of aminoglycosides on glomerular permeability, tubular reabsorption, and intracellular catabolism of the cationic low-molecular-weight protein lysozyme. Toxicol Appl Pharmacol 1983; 68: 96-109. (Pubitemid 13128821)
66. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 2001; 281: F579-F596.
67. Tencer J, Frick IM, Öqvist BW et al. Size-selectivity of the glomerular barrier to high molecular weight proteins: upper size limitations of shunt pathways. Kidney Int 1998; 53: 709-715. (Pubitemid 28124287)
68. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
69. López-Novoa JM, Santos JC, Villamediana LM et al. Renal catabolism of 125I-glicentin. Am J Physiol 1986; 250: E545-E550.